Subscribe to RSS
DOI: 10.1055/s-0042-123110
Herzinfarkt in der Notfallmedizin – Update zu Management und Therapie
Publication History
Publication Date:
02 June 2017 (online)
Das akute Koronarsyndrom (ACS) stellt unverändert eine der häufigsten Diagnosen dar, mit denen das Rettungsdienstpersonal konfrontiert wird. Das Management des ACS beginnt mit dem ersten medizinischen Kontakt durch den Notarzt bzw. das Rettungsdienstpersonal. Für alle Entitäten des Herzinfarktes ist die invasive Diagnostik mit Revaskularisation mittels perkutaner Koronarintervention (PCI) entscheidend für die Prognose.
-
Das akute Koronarsyndrom setzt sich zusammen aus den Entitäten
-
ST-Strecken-Hebungsinfarkt (STEMI),
-
Nicht-ST-Strecken-Hebungsinfarkt (NSTEMI) und
-
instabile Angina pectoris (AP).
-
-
NSTEMI und instabile Angina pectoris unterscheidet sich durch die Erhöhung von Troponin.
-
Für die Therapie ist für alle Entitäten die invasive Diagnostik mit Revaskularisation mittels perkutaner Koronarintervention (PCI) entscheidend, wobei beim STEMI wichtige Zeitvorgaben einzuhalten sind.
-
Prähospitale Medikamentengabe:
-
Für die prähospitale Therapie ist die Gabe von unfraktioniertem Heparin (UFH) und Azetylsalizylsäure (ASS) die Standardmedikation.
-
Die Sauerstoffgabe sollte nur bei reduzierter Sauerstoffsättigung < 95% gegeben werden.
-
Morphingabe nur bei starken Schmerzen.
-
Die Gabe von weiteren Plättcheninhibitoren prähospital hat nach jetzigen Daten keinen Zusatznutzen.
-
-
Für die Auswahl der Zielklinik sollten folgende Faktoren für den Notarzt von Bedeutung sein:
-
eine 24-Stunden-Bereitschaft zur perkutanen Koronarintervention (PCI),
-
optimierte interne Organisation mit kurzen Door-to-Balloon-Zeiten und
-
das Katheterisieren via A. radialis.
-
-
Literatur
- 1 Schnoor J, Gillmann B, Pavlakovic G. et al. Einsatzcharakteristik wiederholter Notarzteinsätze. Notarzt 2006; 22: 141-146
- 2 McManus DD, Gore J, Yarzebski J. et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124: 40-47
- 3 Roffi M, Patrono C, Collet JP. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315
- 4 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
- 5 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619
- 6 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
- 7 Windolph J, Eitel I, Thiele H. Chest Pain Units. Notfallmedizin up2date 2015; 10: 321-336
- 8 Thygesen K, Alpert JS, Jaffe AS. et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567
- 9 Wijesinghe M, Perrin K, Ranchord A. et al. Routine use of oxygen in the treatment of myocardial infarction: systematic review. Heart 2009; 95: 198-202
- 10 Stub D, Smith K, Bernard S. et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015; 131: 2143-2150
- 11 Nehme Z, Stub D, Bernard S. et al. Effect of supplemental oxygen exposure on myocardial injury in ST-elevation myocardial infarction. Heart 2016; 102: 444-451
- 12 Steg PG, James SK, Gersh BJ. 2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient management. Heart 2013; 99: 1156-1157
- 13 Kubica J, Adamski P, Ostrowska M. et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252
- 14 Hobl EL, Stimpfl T, Ebner J. et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63: 630-635
- 15 Giannopoulos G, Deftereos S, Kolokathis F. et al. P2Y12 receptor antagonists and morphine: A dangerous liaison?. Circ Cardiovasc Interv 2016;
- 16 Chatterjee S, Chaudhuri D, Vedanthan R. et al. Early intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis of randomized trials. Int J Cardiol 2013; 168: 915-921
- 17 Mateos A, García-Lunar I, García-Ruiz J. et al. Efficacy and safety of out-of-hospital intravenous metoprolol administration in anterior ST-segment elevation acute myocardial infarction: insights from the METOCARD-CNIC trial. Ann Emerg Med 2015; 65: 318-324
- 18 Roolvink V, Ibáñez B, Ottervanger JP. et al. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol 2016; 67: 2705-2715
- 19 Montalescot G, Wiviott SD, Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731
- 20 Steg PG, James S, Harrington RA. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-2141
- 21 Montalescot G, van ʼt Hof AW, Lapostolle F. et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027
- 22 Montalescot G, Bolognese L, Dudek D. et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010
- 23 Shahzad A, Kemp I, Mars C. et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384: 1849-1858
- 24 Valgimigli M, Frigoli E, Leonardi S. et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015; 373: 997-1009
- 25 Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014; 384: 599-606
- 26 Eitel I, Desch S, De Waha S. et al. Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart 2011; 97: 2038-2045
- 27 Eitel I, Desch S, Fuernau G. et al. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010; 55: 2470-2479
- 28 Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death: myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794
- 29 Terkelsen CJ, Lassen JF, Norgaard BL. et al. Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital diagnosis and direct referral to primary percutaneous coronary intervention. Eur Heart J 2005; 26: 770-777
- 30 Terkelsen CJ, Sorensen JT, Maeng M. et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010; 304: 763-771
- 31 Palmerini T, Biondi-Zoccai G, Della Riva D. et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: Evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013; 62: 496-504
- 32 Jang JS, Jin HY, Seo JS. et al. The transradial versus the transfemoral approach for primary percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention 2012; 8: 501-510
- 33 Mehta SR, Jolly SS, Cairns J. et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 2012; 60: 2490-2499
- 34 Valgimigli M, Gagnor A, Calabró P. et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015; 385: 2465-2476